Dr. Reddy’s Laboratories on Friday posted December third quarter consolidated net profit at ₹ 20 crore compared with a loss of ₹ 569.7 crore in the year-ago period.
The company said the Q3FY21 profit after tax (PAT) was affected majorly due to the non-recognition of deferred tax assets on impairment.
Revenue for the said quarter came at ₹ 4,930 crore that was up 12 per cent year-over-year and 1 per cent quarter-over-quarter.
Gross margin stood at 53.8 per cent compared with 54.1 per cent year-over-year and 53.9 per cent quarter-over-quarter.
Selling, general and administrative expenses (SGNA) expenses rose 14 per cent year-over-year and 10 per cent quarter-over-quarter to ₹ 1,439 crore. Research and Development (R&D) expenses stood at ₹ 411 crore for the quarter.